undefined undefined
NaN.000
NaN.00%
Analyst Jason McCarthy from Maxim Group reiterated a Buy rating on Aprea Therap...
04-12 23:35
Gainers Tevogen Bio Holdings (NASDAQ:TVGN) stock rose 85.5% to $4.86 during Th...
04-04 20:09
Aprea Therapeutics (NASDAQ:APRE) reported its Q4 earnings results on Tuesday, M...
03-26 21:10
Aprea Therapeutics press release (NASDAQ:APRE): Q4 GAAP EPS of -$0.92. $21.6 million in cash and cash equivalents as of December 31, 2023 Private placement financing in March 2024 raised upfront gross...
03-26 20:05
FDA clearance for Aprea Therapeutics' APR-1051 IND application, a promising WEE1 kinase inhibitor. Phase 1 trial initiation in 2024, focusing on Cyclin E cancers. $34 million private placement to fund clinical development and ensure company sustainability until 2026.
03-11 21:39
DUO: 151% | Fangdd Network shares are trading higher after the company announced its 2024 strategic layout with plans to enter the real estate stock asset services sector MESO: 52% | United States
03-11 20:40
Financing led by Sphera Healthcare with participation from new and existing healthcare-focused institutional investors $16.0 million in upfront gross proceeds with the potential to receive up to an additional $18.0
03-11 20:32
Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.86) per share which beat the analyst consensus estimate of $(1.16) by 25.86 percent. This is a 64.17 percent increase over losses of $(2.40) per share
2023-11-10 06:27
What are Value Stocks? A value stock traditionally has a lower price when compa...
2023-09-25 22:44
What is the target price for Aprea Therapeutics (APRE)? The latest price tar...
2023-09-13 18:30